Apellis Pharmaceuticals Inc APLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APLS is a good fit for your portfolio.
News
-
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
-
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
-
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
-
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
-
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
-
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Trading Information
- Previous Close Price
- $41.20
- Day Range
- $41.44–43.41
- 52-Week Range
- $19.83–94.75
- Bid/Ask
- $41.44 / $42.63
- Market Cap
- $5.09 Bil
- Volume/Avg
- 1.0 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 702
- Website
- https://www.apellis.com
Comparables
Valuation
|
Metric
|
APLS
|
CRNX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 18.73 | 4.43 | 5.43 |
Price/Sales | 9.51 | 1,567.62 | 19.05 |
Price/Cash Flow | — | — | 373.37 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
APLS
|
CRNX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 2.78 | 17.59 | 5.32 |
Current Ratio | 3.77 | 17.72 | 5.46 |
Interest Coverage | −13.74 | — | −22.10 |
Quick Ratio
APLS
CRNX
ACLX
Profitability
|
Metric
|
APLS
|
CRNX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −38.34% | −33.04% | −1.99% |
Return on Equity (Normalized) | −114.50% | −37.88% | −3.75% |
Return on Invested Capital (Normalized) | −81.23% | −39.10% | −7.24% |
Return on Assets
APLS
CRNX
ACLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lfmbffvw | Sjw | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zjhzrnwl | Ccqdvqj | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cgdpckyl | Qwybfm | $107.6 Bil | |
MRNA
| Moderna Inc | Gmlcvqcfw | Myvb | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Mxhpvhl | Tptd | $22.2 Bil | |
ARGX
| argenx SE ADR | Pdwrbdv | Fybf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tyzjktdjp | Xnqws | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ztdpnhxnp | Wxkjwv | $15.1 Bil | |
INCY
| Incyte Corp | Snztgjpyc | Djxtx | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fwkkcyzm | Lljvb | $12.7 Bil |